Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: A randomized double-blind placebo-controlled study

Diabetes, Obesity and Metabolism

Volumn 12, Issue 3, 2010, Pages 246-251

  Kondo, K ^a   Kadowaki, T ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Colestilan; Double blind randomized clinical trial; Fasting plasma glucose; HbA 1c; LDL cholesterol

Indexed keywords

CHOLESTEROL; COLESTILAN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; ECZEMA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; JAPAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 75649151208     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01159.x     Document Type: Article

References (21)

1. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988, 116:1713-1724.
2. Okamura T, Tanaka H, Miyamatsu N. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 2007, 190:216-223.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
4. Turner RC, Millns H, Neil HAW. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
5. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007, 14:567-580.
6. Kawabata Y, Ikegami H, Fujisawa T. Bile-acid binding resin ameliorates glycemic control in patients with type 2 diabetes. Diabetes 2006, 55(Suppl. 1):120.
7. Suzuki T, Oba K, Futami S. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006, 73:277-284.
8. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007, 54:53-58.
9. The long-term study of MCI-196 on hypercholesterolemia. Rinsho Iyaku 1996, 12:1305-1347. MCI-196 Study Group, [In Japanese].
10. Hata M, Uchiyama K, Kajiura T, Ishibashi A. Postmarketing prospective cohort study of a cholesterol lowering drug, colestilan preparations, Cholebine®. Shinyaku To Rinsho 2008, 57:754-773. [In Japanese].
11. Kato D, Sawai Y, Kanayama H. Evaluation of the efficacy of colestimide in diabetes mellitus complicated by dyslipidemia and metabolic syndrome. Diabetes Front 2007, 18:693-696. [In Japanese].
12. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
13. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial: Lancet. 2003, 361:2005-2016. Heart Protection Study Group
14. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910. DAIS Investigators
15. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomized controlled trial. Lancet 2005, 366:1849-1861. The FIELD Study Investigators
16. Fujishima M, Kiyohara Y, Kato I. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996, 45(Suppl):S14-S16.
17. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007, 67:1383-1392.
18. Kobayashi M, Ikegami H, Fujisawa T. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007, 56:239-247.
19. Duran-Sandoval D, Cariou B, Percevault F. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005, 280:29971-29979.
20. Abhimanyu G, Scott MG. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 1994, 121:414-422.
21. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5:16-17.